Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Paradox Immunotherapeutics
Deal Size : $10.0 million
Deal Type : Financing
Paradox Gets $10M from SymBiosis to Advance Protein Misfolding Disease Therapies
Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Paradox Immunotherapeutics
Deal Size : $10.0 million
Deal Type : Financing
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Recipient : Clene Nanomedicine
Deal Size : $7.3 million
Deal Type : Public Offering
Clene Closes $7.3M Offering and Amends Debt Facility for Ongoing Initiatives
Details : The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
January 10, 2024
Lead Product(s) : CNM-Au8
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Recipient : Clene Nanomedicine
Deal Size : $7.3 million
Deal Type : Public Offering
Lead Product(s) : EO2401,Bevacizumab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Enterome
Deal Size : $52.6 million
Deal Type : Financing
Details : Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 25, 2020
Lead Product(s) : EO2401,Bevacizumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Enterome
Deal Size : $52.6 million
Deal Type : Financing
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture
Details : Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 22, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : MaaT Pharma
Deal Size : $19.5 million
Deal Type : Series B Financing
MaaT Pharma Announces €18 Million Series B Financing
Details : The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 02, 2020
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : MaaT Pharma
Deal Size : $19.5 million
Deal Type : Series B Financing